GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: JAZZ
Outperform $200

JAZZ PHARMA INC (NASDAQ: JAZZ) rated to Outperform with price target $200 by BMO Capital Markets

Friday,  Feb 20, 2015  1:25 PM ET by Kristen Bailey

BMO Capital Markets rated JAZZ
PHARMA INC (NASDAQ: JAZZ) to Outperform with price target $200.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

The U.S. Equity Research team comprises over 25 analysts located in New York, Atlanta, Boston, Denver, Houston and Los Angeles. We cover more than 375 stocks and also provide equity strategy, quantitative analysis and portfolio management services to our clients. Our goal is to identify the best sectors to invest in, and the best stocks within those sectors, in order to help our clients maximize their portfolio returns. Our award-winning analysts provide research that is informative, perceptive and actionable.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy